Method and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways
The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.
1 . A method for typing a RNA sample of a human individual suffering from colorectal cancer, or suspected of suffering therefrom, the method comprising:
a. providing a tissue sample from said individual, said tissue sample comprising colorectal cancer cells or suspected to comprise colorectal cancer cells;
b. preparing an RNA sample from said tissue sample;
c. labelling RNA products, or cDNA products thereof, that are present in said RNA sample;
c. measuring an abundance of at least five labelled RNA products or cDNA products by RNA sequencing procedures; wherein said at least five labelled RNA products or cDNA products comprise TRIM7 of Table 2; and
d. typing said RNA sample as having one or more activating mutations in a BRAF-pathway or as not having an activating mutation in the BRAF-pathway, on the basis of the measured abundance of said at least five labelled RNA or cDNA products.
2 . The method of claim 1 , wherein an abundance is determined of all RNA or cDNA products indicated by Table 2.
3 . The method according to claim 1 , further comprising normalizing the determined abundance of RNA products or cDNA products in said sample.
4 . A method of classifying a human individual suffering from colorectal cancer, comprising:
classifying said individual as having one or more activating mutations in a BRAF-pathway or not having an activating mutation in the BRAF-pathway by a method comprising:
(a) providing a tissue sample from said individual, said tissue sample comprising colorectal cancer cells or suspected to comprise colorectal cancer cells;
(b) preparing an RNA sample from said tissue sample;
(c) labelling said RNA sample, RNA products, or cDNA products thereof, for detection;
(d) measuring in said sample an abundance of at least five labelled RNA products or cDNA products by RNA sequencing procedures; wherein said at least five labelled RNA products or cDNA products comprise TRIM7 of Table 2;
(e) determining a first similarity value between an abundance of said at least five labelled RNA products or cDNA products in said sample and an abundance of said at least five labelled RNA products or cDNA products in a profile template that is representative of samples not having an activating mutation in the BRAF pathway;
(f) determining a second similarity value between an abundance of said at least five labelled RNA products or cDNA products in said sample and an abundance of said at least five labelled RNA products or cDNA products in profile template that is representative of samples having an activating mutation in the BRAF pathway;
(g) determining a difference value between the first similarity value and the second similarity value; and
(h) classifying said individual as having an activating mutation in the BRAF pathway if said difference value is below a similarity threshold value, and classifying said individual as not having an activating mutation in the BRAF pathway if said similarity value exceeds said similarity threshold value.
5 . The method of claim 4 , whereby only one profile template is used for typing a sample.
6 . The method of claim 4 , whereby an abundance is determined of all RNA products or cDNA products indicated by Table 2.
7 . The method of claim 4 , whereby normalized abundances of RNA products or cDNA products are used to determine a similarity value.
8 . A method for measuring the abundance of at least five labelled RNA products or cDNA products comprise TRIM7 of Table 2, the method comprising:
(a) providing a tissue sample from said individual, said tissue sample comprising colorectal cancer cells or suspected to comprise colorectal cancer cells;
(b) preparing an RNA sample from said tissue sample;
(c) labelling RNA products, or cDNA products thereof, that are present in said RNA sample; and
(d) measuring the abundance of at least five labelled RNA products or cDNA products by RNA sequencing procedures; wherein said at least five labelled RNA products or cDNA products comprise TRIM7 of Table 2.